Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells.
In addition to their stimulating function on osteoclastic bone resorption, bone resorptive factors may regulate proteinases and related factors in osteoblastic cells to degrade bone matrix proteins. This study investigated the regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in the cultures of mouse osteoblastic MC3T3-E1 cells, mouse primary osteoblastic (POB) cells, and neonatal mouse calvariae. Expression of either MMP-2, -3, -9, -11, -13, and -14 or TIMP-1, -2, and -3 was detected in MC3T3-E1 cells and POB cells. When the bone resorptive factors parathyroid hormone, 1,25-dihydroxyvitamin D(3), prostaglandin E(2), interleukin-1beta (IL-1beta), and tumor necrosis factor-alpha (TNF-alpha) were added to the cell cultures, MMP-13 mRNA levels were found predominantly to increase by all resorptive factors in the three cultures. mRNA levels of either MMP-3 and -9 or TIMP-1 and -3 were found to increase mainly by the cytokines IL-1beta and TNF-alpha. BB94, a nonselective MMP inhibitor, neutralized the (45)Ca release stimulated by these resorptive factors to an extent similar to that of calcitonin, strongly suggesting that bone resorptive factors function at least partly through MMP formation. We propose that MMP-13 mRNA expression in osteoblastic cells may play an important role in stimulating matrix degradation by both systemic and local resorptive factors, whereas either MMP-3 and -9 or TIMP-1 and -3 might modulate matrix degradation by local cytokines only.
Uchida
M
M
Biomedical Research Laboratories, Kureha Chemical Industry Company, Ltd., Tokyo, Japan.
Shima
M
M
Shimoaka
T
T
Fujieda
A
A
Obara
K
K
Suzuki
H
H
Nagai
Y
Y
Ikeda
T
T
Yamato
H
H
Kawaguchi
H
H
D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism; D001862:Bone Resorption / Q000503:physiopathology; D002352:Carrier Proteins / Q000494:pharmacology; D002460:Cell Line; D016207:Cytokines / Q000502:physiology*; D018093:Gelatinases / Q000378:metabolism; D006728:Hormones / Q000494:pharmacology; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D010006:Osteoblasts / Q000378:metabolism / Q000502:physiology*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D012886:Skull / Q000187:drug effects / Q000378:metabolism; D013876:Thiophenes / Q000494:pharmacology; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*
D002352:Carrier Proteins; D016207:Cytokines; D006728:Hormones; D061965:Matrix Metalloproteinase Inhibitors; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D013876:Thiophenes; D019714:Tissue Inhibitor of Metalloproteinases; C505687:Tnfrsf11a protein, mouse; C505689:Tnfsf11 protein, mouse; C025940:bone resorption factor; D010649:Phenylalanine; C080985:batimastat; D018093:Gelatinases; D020782:Matrix Metalloproteinases